Open Access
CC BY-NC-ND 4.0 · Endoscopy 2018; 06(05): E513-E517
DOI: 10.1055/s-0044-102097
Original article
Owner and Copyright © Georg Thieme Verlag KG 2018

Novel temperature-controlled RFA probe for treatment of blocked metal biliary stents in patients with pancreaticobiliary cancers: initial experience

Authors

  • Manu K. Nayar

    HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
  • Kofi W. Oppong

    HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
  • Noor L.H. Bekkali

    HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
  • John S. Leeds

    HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Further Information

Publication History

submitted 07 August 2017

accepted after revision 19 January 2018

Publication Date:
18 April 2018 (online)

Abstract

Background and study aims Radiofrequency ablation (RFA) is used to treat blocked biliary stents in patients with pancreaticobiliary (PB) tumors with varying results. We report our experience with a novel temperature-controlled probe for treatment of blocked metal stents.

Patients and methods Patients with histologically proven PB cancers and a blocked biliary stents were treated using ELRATM electrode (Taewoong Medical) under fluoroscopic guidance. Demographics, clinical outcome, stricture diameter improvements, complications and mortality at 30 days were prospectively recorded.

Results Nine procedures were performed on seven patients (4 male, 3 female); mean age 65.33 (range 56 – 82 years). Mean stricture diameter prior to RFA was 1.13 mm (SD ± 0.54) and 4.42 mm (SD ± 1.54) following RFA (P < 0.0001). Five of seven patients (71 %) required additional stents to ensure optimal drainage. There were no procedure-related complications. Mean follow-up was 193.55 days (range 31 – 540) and three of nine patients (33 %) died due to terminal cancer.

Conclusion These are the first reported data on use of a temperature-controlled RFA catheter in humans to treat blocked metal biliary stents. The device is safe but further randomized trials are required to establish the efficacy and survival benefits of this probe.